Abiopharma

🔍 Cornell Brian C (Director)

Company: TARGET CORP (TGT)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Sold 50,000 shares of Common Stock at $163.5556 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 143,270.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | shares_owned_after: 134,733.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 500.26 | Footnotes: F3

Footnotes:

• F1: Price is the volume weighted average selling price of all sales by the reporting person on the transaction date within a one dollar range. Actual prices ranged from $163.0250 to $164.0250. The reporting person hereby undertakes to provide upon request of the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• F2: Includes dividend equivalents paid on restricted stock units and performance-based restricted stock units since the date of the reporting person's last filing through the date of the reported transaction that have been reinvested in additional restricted stock units and performance-based restricted stock units.
• F3: Shares held in the Target Corporation 401(k) Plan based on the plan statement as of June 30, 2026.